KIR3DL3, as the second receptor of HHLA2, is mainly expressed in terminal differentiation effector memory CD8+ T cells and CD56dim CD16+ NK cells, which mediates co-inhibition of CD8+ T cells and NK cells and induces HHLA2+ tumor tolerance against tumor killing (24). Here, HHLA2 is linked to neoplasm.